Stocktoria
enVVeno Medical Corp NVNO
enVVeno Medical Corp (NVNO) earns a Piotroski F-score of 1/9 (weak financial health), with an Altman Z″ in the distress zone. It does not currently pay a dividend.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 1/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · distress zone
| Component | Value |
|---|---|
| Working capital / assets | 0.903 |
| Retained earnings / assets | -5.796 |
| EBIT / assets | -0.707 |
| Equity / liabilities | 11.155 |
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| NVNO | enVVeno Medical Corp | 1/9 | -6.01 | — | — |
| MDLN | Medline Inc. | 6/9 | 2.84 | 44.1 | +11.5% |
| SYK | STRYKER CORP | 4/9 | 3.96 | 39.3 | +11.2% |
| MMM | 3M CO | 5/9 | 5.46 | 26.3 | +1.5% |
| BDX | BECTON DICKINSON & CO | 6/9 | 2.29 | 25.6 | +8.2% |
| BSX | BOSTON SCIENTIFIC CORP | 4/9 | 2.81 | — | +19.9% |
| BAX | BAXTER INTERNATIONAL INC | 5/9 | 3.86 | — | +5.7% |
About enVVeno Medical Corp
enVVeno Medical Corporation, a medical device company, focuses on the development of bioprosthetic tissue-based solutions to enhance the standard of care in the treatment of venous disease in the United States. The company's lead product is the VenoValve, a surgical replacement venous valve for the treatment of venous chronic venous insufficiency. Its VenoValve implanted into the femoral vein of the patient in an open surgical procedure via a 5-to-6-inch incision in the upper thigh. The company also develops enVVe, a non-surgical and transcatheter-based replacement venous valve system consisting of the enVVe valve, enVVe delivery system, and delivery system accessories. The company was formerly known as Hancock Jaffe Laboratories, Inc. and changed its name to enVVeno Medical Corporation in October 2021. enVVeno Medical Corporation was incorporated in 1999 and is based in Irvine, California.
FAQ
Is NVNO financially healthy?
enVVeno Medical Corp's Piotroski F-score is 1/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the distress zone.
Does NVNO pay a dividend?
No, enVVeno Medical Corp does not currently pay a dividend.
How profitable is NVNO?
In FY2025, enVVeno Medical Corp had a return on equity of -71.8%.
Is NVNO a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on enVVeno Medical Corp: a Piotroski F-score of 1/9, an Altman Z″ in the distress zone. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.